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Summary
To determine the impact of tumor progression on the reversibility of Neu-induced tumorigenesis, we have used the
tetracycline regulatory system to conditionally express activated Neu in the mammary epithelium of transgenic mice. When
induced with doxycycline, bitransgenic MMTV-rtTA/TetO-NeuNT mice develop multiple invasive mammary carcinomas,
essentially all of which regress to a clinically undetectable state following transgene deinduction. This demonstrates that
Neu-initiated tumorigenesis is reversible. Strikingly, extensive lung metastases arising from Neu-induced mammary tumors
also rapidly and fully regress following the abrogation of Neu expression. However, despite the near universal dependence
of both primary tumors and metastases on Neu transgene expression, most animals bearing fully regressed Neu-induced
tumors ultimately develop recurrent tumors that have progressed to a Neu-independent state.
Introduction efficacy of this agent against HER2/Neu-amplified breast can-
cers even in advanced stages of this disease (Baselga et al.,
Breast cancer is the most common malignancy diagnosed 1996; Cobleigh et al., 1999; Slamon et al, 2001; Vogel et al.,
among women in the United States and is the second leading 2002; Wang and Hung, 2001; Wang et al., 2001). However, while
cause of cancer mortality. While the efficacy of several chemo- Trastuzumab—either alone or in combination with standard che-
therapeutic approaches to this disease has been demonstrated, motherapeutic regimens—slows disease progression and im-
proves survival, these cancers typically recur and become resis-a major obstacle to the successful treatment of breast cancer
has been the inability to effectively treat metastatic disease or tant to the therapeutic targeting of this pathway (Hortobagyi,
2001). The mechanism by which HER2/Neu-amplified breastprevent tumor recurrence, each of which ultimately leads to
treatment failure and death. tumor cells progress to a state that is independent of increased
HER2/neu activity is unknown. As such, identifying secondaryRecently, novel therapeutic strategies have been developed
that specifically target oncogenic pathways activated in sub- pathways that permit cancers to evade anti-HER2/Neu therapy
is a critical next step in the development of more effectiveclasses of tumors. For example, amplification and overexpres-
sion of the protooncogene, HER2/Neu, occurs in 15%–30% of therapeutic approaches for this aggressive subset of tumors.
Toward this goal, mouse models of breast cancer initiatedprimary human breast cancers and is associated with aggres-
sive tumor behavior, decreased time to relapse, and poor prog- by defined oncogenic events relevant to breast cancer in hu-
mans have proven useful for investigating the process of tumori-nosis (Berger et al., 1988; Slamon et al., 1987). Clinical trials
utilizing the neutralizing antibody Trastuzumab, which targets genesis. For example, transgenic mice in which either wild-
type Neu (c-Neu) or activated Neu (NeuNT) is constitutivelythe HER2/Neu receptor tyrosine kinase, have demonstrated the
S I G N I F I C A N C E
The question of whether tumor progression impacts on the reversibility of oncogene-initiated events has important clinical implications
for cancer therapy. Our data demonstrate that the vast majority of cells within even the most advanced stages of epithelial malignancy,
namely metastases, remain dependent upon an initiating oncogenic event for maintenance of the transformed state. Nevertheless,
we show that Neu-initiated mammary tumors commonly progress to a Neu-independent state and that the majority of animals
bearing fully regressed tumors harbor residual neoplastic disease long after the apparently complete regression of their tumors.
These findings challenge the assertion that all oncogene-initiated events are reversible and highlight the importance of determining
the mechanisms by which tumor cells escape from their dependence on individual oncogenic pathways.
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overexpressed in the mammary gland develop invasive mam- doxycycline induction (Figure 1C, left panels). Similarly, hema-
toxylin and eosin-stained sections from the mammary glandsmary adenocarcinomas (Bouchard et al., 1989; Guy et al., 1992;
Muller et al., 1988). However, the extent to which established of induced MTB/TAN mice displayed extensive ductal hyperpla-
sias and abnormal development, including the formation of mul-Neu-induced tumors and metastatic lesions remain dependent
upon this oncogenic signaling pathway for maintenance of the tiple solid cellular masses along the primary ducts that resemble
abortive side buds (Figure 1C, center and right panels). In con-transformed state is unknown.
To address these questions, we have used the tetracycline trast, mammary tissues from uninduced MTB/TAN animals were
morphologically and histologically indistinguishable from thoseregulatory system to conditionally express activated Neu in the
mammary epithelium of transgenic mice. When induced with of wild-type and MTB animals (Figure 1C and data not shown).
doxycycline, these mice develop multiple invasive mammary
adenocarcinomas that metastasize to the lungs. Using this MTB/TAN animals develop invasive mammary carcinomas
Treatment of MTB/TAN animals with doxycycline for 21 daysmodel, we show that targeted downregulation of the Neu path-
way results in the rapid disappearance of essentially all Neu- resulted in progressive hyperplastic changes that were particu-
larly prominent in terminal end buds at the growing ends ofinitiated invasive primary tumors as well as pulmonary metasta-
ses. Our findings demonstrate that, despite the multiple genetic ducts (Figure 2A, left panels). Terminal end buds were increased
in size and surrounded by extensive clusters of acinar-like struc-events that are required for tumorigenesis and acquisition of
the metastatic phenotype, even the most advanced stages of tures, many of which were separated by large blood vessels
(Figure 2A, center and right panels, and data not shown). TheseNeu-initiated malignancy remain dependent upon a single onco-
genic mutation for growth and survival. However, consistent histological changes are typical of those induced by the ErbB2
signaling pathway (Cardiff et al., 2000; Cardiff and Muller, 1993).with the natural history of human cancers, we show that the
majority of mice bearing fully regressed Neu-induced mammary Mammary glands from doxycycline-treated MTB and TAN con-
trols and from MTB/TAN animals maintained in the absence oftumors ultimately develop recurrences in the absence of Neu
expression. This indicates that these animals harbor subpopula- doxycycline for more than a year did not display any morphologi-
cal abnormalities (Figure 2A and data not shown).tions of residual neoplastic cells that are eventually able to
bypass their requirement for Neu to reestablish the malignant Consistent with the profound hyperplastic changes noted
above, chronic induction of NeuNT transgene expression inphenotype.
MTB/TAN animals with 2 mg/ml doxycycline resulted in the
rapid development of multiple mammary tumors with 100%Results
penetrance and a latency of 6 weeks (Figure 2B). Tumors arose
stochastically and were focal in nature, although essentiallyDoxycycline-inducible expression of activated Neu
The c-Neu receptor tyrosine kinase is rendered constitutively all mammary glands in chronically induced MTB/TAN animals
harbored tumors. No tumors were observed in uninduced MTB/active and oncogenic by a point mutation in its transmembrane
domain (Bargmann et al., 1986). Mice capable of conditionally TAN animals or in doxycycline-treated MTB and TAN controls
over periods exceeding one year (Figure 2B).expressing this oncogenic form of Neu were generated using
the tetracycline regulatory system by cloning the coding se- Histological analysis of mammary tumors arising in doxycy-
cline-induced MTB/TAN mice revealed invasive solid nodularquence of activated Neu (NeuNT) downstream of the minimal
tet operator. Additionally, an IRES-firefly luciferase expression carcinomas typical of Neu/ErbB2-initiated mammary tumors
(Cardiff et al., 2000; Cardiff and Muller, 1993; Muller et al., 1988).cassette was cloned downstream of activated Neu to serve as
a surrogate reporter for transgene expression. Founder mice Tumor cells possessed bland, uniform oval nuclei, abundant
pink-red cytoplasm, and lacked significant glandular differentia-harboring this TetO-NeuNT transgene, referred to as TAN, were
generated and mated to a previously described line of MMTV- tion as is typical of the “intermediate cells” of Neu/ErbB2 tumors
(Figure 2C, left panel). Small nests of intermediate cells werertTA transgenic mice (MTB) to yield bitransgenic MTB/TAN off-
spring (D’Cruz et al., 2001; Gunther et al., 2002). subdivided by a rich microvasculature. An additional phenotype,
which has not been previously described in Neu/ErbB2 trans-To determine whether this system would permit the condi-
tional expression of activated Neu in a mammary-specific and genics, was identified in several tumors consisting of nests and
cords of nodular cells with bright red cytoplasm invading adoxycycline-dependent manner, transgene expression levels
were determined by Northern hybridization analysis and mea- dense, vascular stroma (Figure 2C, center panel). These tumors
resemble the most common type of human breast cancers thatsurement of luciferase activity (Figure 1). Analysis by these meth-
ods of mammary tissues harvested from female MTB/TAN mice are currently classified as “breast cancer, no specific type”
(Cardiff and Wellings, 1999; Maglione et al., 2001). Immunohis-following four days of doxycycline treatment revealed high levels
of induction of activated Neu mRNA expression (Figure 1A). tochemical analysis using anti-Neu and anti-Cytokeratin 8 anti-
Similarly, luciferase activity in the mammary glands of induced bodies confirmed that all Neu-initiated tumors express high
MTB/TAN mice increased approximately 10,000-fold over base- levels of Neu protein and are of luminal epithelial origin (Figure
line (Figure 1B). In contrast, transgene expression in the mam- 2C, right panel and data not shown).
mary glands of uninduced MTB/TAN animals as well as doxycy-
cline-treated wild-type and MTB controls was undetectable Invasive mammary carcinomas require Neu
for tumor maintenanceeither by Northern hybridization analysis or by analysis of lucifer-
ase activity (Figures 1A and 1B and data not shown). The focal nature and stochastic appearance of mammary tu-
mors in MTB/TAN mice suggested that additional genetic alter-Morphological examination of carmine-stained whole mounts
revealed striking hyperplastic abnormalities in the mammary ations were likely to be required for Neu-induced tumorigenesis.
We wished to determine whether invasive mammary carcinomasductal trees of induced MTB/TAN mice following four days of
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Figure 1. Doxycycline-dependent expression of NeuNT results in abnormal alveolar development
A: Northern analysis of total RNA from mammary glands of 6.5 week MTB and MTB/TAN animals maintained on doxycycline for 4 days. The blot was probed
with a DNA fragment specific for Neu. 28S rRNA is shown as a loading control.
B: Luciferase activity assays performed on mammary tissue from 6.5 week MTB and MTB/TAN animals maintained on doxycycline for 4 days. Assays were
performed in triplicate and relative light units were normalized to total protein levels.
C: Carmine-stained whole mounts (left panels, magnification 25) and hematoxylin and eosin (H&E)-stained sections of mammary glands (middle and
right panels, magnification 200 and 400) from 6.5 week MTB/TAN animals administered doxycycline for 4 days and uninduced MTB/TAN controls.
arising in MTB/TAN mice remained dependent upon Neu for to be a hemorrhagic cyst, whereas two tumors regressed par-
tially and then resumed growth. Neither of these expressedmaintenance of the transformed state or, alternately, whether
secondary mutations that occur during the process of tumori- detectable levels of the NeuNT transgene (data not shown).
These findings demonstrate that the vast majority of epithelialgenesis render Neu dispensable for tumor growth and survival.
To address this question, doxycycline was withdrawn from a cells within Neu-induced tumors remain dependent upon Neu
for maintenance of the transformed state.cohort of chronically induced tumor-bearing MTB/TAN animals,
each of which harbored multiple palpable mammary tumors To analyze the cellular mechanism of regression in Neu-
induced mammary tumors, doxycycline was withdrawn from anranging in size from 25 to 360 mm2 . Northern hybridization
analysis demonstrated that NeuNT transgene expression was independent set of MTB/TAN mice harboring tumors and ani-
mals were sacrificed 48 hr later following labeling with BrdU.rapidly downregulated in primary tumors within 24 hr following
doxycycline withdrawal and was undetectable within 48 hr (Fig- Anti-BrdU immunohistochemistry revealed that cellular prolifer-
ation rates were dramatically downregulated in Neu-inducedure 3A). Strikingly, 44 of 47 tumors (94%) rapidly and fully re-
gressed to a nonpalpable state following doxycycline with- tumors within 48 hr following doxycycline withdrawal (Figure
3D, center panels). Conversely, whereas apoptotic cells weredrawal with a mean time to complete regression of 17  12
days (Figures 3B and 3C). Of the three tumors that failed to rarely detected in tumors harvested from mice maintained on
doxycycline, marked increases in the numbers of TUNEL-posi-regress completely, one was determined at the time of sacrifice
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Figure 2. MTB/TAN mice maintained chronically on doxycycline develop mammary adenocarcinomas
A: Carmine-stained whole mounts (left panels, magnification 50) and H&E-stained sections (center and right panels, magnification 200 and 800) of
mammary glands from 9 week MTB/TAN mice maintained on doxycycline for 21 days.
B: Tumor-free survival curve for MTB/TAN (n  26), TAN (n  8), and MTB (n  10) mice chronically administered 2 mg/ml doxycycline, and MTB/TAN (n 
13) mice maintained off doxycycline.
C: H&E-stained sections from tumors with characteristic Neu phenotype (left panel) and atypical Neu phenotype (middle panel) and anti-Neu immunohisto-
chemistry (right panel) performed on a tumor arising in an MTB/TAN animal. Magnification 200.
tive cells were observed in tumors harvested from animals 48 Pulmonary metastases remain dependent upon Neu
A large percentage of MTB/TAN animals bearing primary mam-hr following doxycycline withdrawal (Figure 3D, right panels).
These results suggest that the initial phase of tumor regression mary tumors eventually develop a distinctive ill phenotype char-
acterized by hunched posture, ruffled fur and labored breathingin MTB/TAN animals induced by Neu transgene downregulation
is due to decreased proliferation and increased apoptosis. that is uniformly fatal within one week. Examination of the lungs
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Figure 3. NeuNT-induced tumors regress fully following withdrawal of the NeuNT stimulus
A: Northern analysis of total RNA from MTB/TAN tumors harvested in the presence of doxycycline and 24 or 48 hr after doxycycline withdrawal. The blot
was probed for Neu. Mammary gland samples harvested from MTB and MTB/TAN animals maintained on doxycycline for 96 hr are shown as controls. 28S
rRNA is shown as a loading control.
B: Representative graphs depicting the growth and regression of two tumors in a mouse from which doxycycline was withdrawn. Doxycycline was removed
on day 102.
C: Photographs of a chronically induced MTB/TAN animal at the time of doxycycline withdrawal (d0) and on the 6th (d6) or 21st day (d21) following
doxycycline withdrawal.
D: H&E-stained sections, anti-BrdU immunohistochemistry, and TUNEL analysis of MTB/TAN tumors harvested in the presence of doxycycline and 48 hr
following doxycycline withdrawal. Magnification 800.
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Figure 4. Grafted pulmonary metastases from
tumor-bearing MTB/TAN mice are reversible
A: Gross pathology (3.2) and H&E-stained sec-
tion (100) of lungs containing pulmonary me-
tastases harvested from chronically induced
MTB/TAN animals bearing primary mammary tu-
mors.
B: Representative graphs displaying growth on
doxycycline and regression following doxycy-
cline withdrawal leading either to complete (top
panel) or to partial (bottom panel) regression of
pulmonary metastasis grafts implanted on the
flanks of syngeneic hosts.
from 26 animals exhibiting this phenotype revealed that 24 pable state following doxycycline withdrawal (Table 1). Five
grafts in each group regressed only partially and then resumed(92%) harbored grossly visible solid pulmonary nodules on the
growth, whereas one graft in each group regressed partially,pleural surface (Figure 4A, left panel). Microscopic analysis con-
but did not resume growth (Table 1 and Figure 4B). Of note,firmed that these nodules were pulmonary metastases with his-
none of the grafts that resumed growth expressed the NeuNTtological features characteristic of Neu-induced mammary epi-
transgene or detectable levels of endogenous ErbB2 (data notthelial carcinomas (Figure 4A, right panel). Luciferase activity
shown). These observations demonstrate that the majority oflevels in lungs bearing metastatic lesions were comparable to
grafted pulmonary metastases in MTB/TAN mice remain depen-levels detected in the primary mammary tumors (data not
dent upon Neu for maintenance of the transformed state.shown).
The apparent discrepancy between the fractions of primaryDespite our observation that NeuNT-induced primary mam-
mammary tumors and grafted primary mammary tumors thatmary tumors remain dependent upon Neu expression for main-
regressed fully following doxycycline withdrawal (94% versustenance of the transformed state, we considered the possibility
57%, respectively) suggested that genetic alterations that ren-that the same genetic alterations that confer the aggressive
der tumor cells independent of Neu might occur during thegrowth properties required for Neu-induced mammary tumor
outgrowth of tumor grafts, but not during the process of tumori-cells to metastasize might also facilitate the progression of tu-
genesis in situ. This, along with the consistent resolution ofmor cells to a Neu-independent state. To address this question,
respiratory symptoms noted following doxycycline withdrawaldoxycycline treatment was withdrawn from a cohort of chroni-
from tumor-bearing mice, suggested that an even greater frac-cally induced, tumor-bearing MTB/TAN animals that had devel-
tion of pulmonary metastases in situ may remain dependent onoped the characteristic respiratory phenotype described above
NeuNT transgene expression for maintenance of the trans-associated with pulmonary metastases. Whereas this condition
formed state.is uniformly fatal in animals maintained on doxycycline, all 9
To test this hypothesis directly, magnetic resonance imagingtumor-bearing mice displaying this phenotype at the time of
was performed on tumor-bearing MTB/TAN mice that had devel-doxycycline withdrawal rapidly recovered and resumed a normal
respiratory rate. Given the high degree of correlation between
the respiratory phenotype observed in tumor-bearing MTB/TAN
animals and the presence of pulmonary metastases, our obser-
Table 1. Regression of primary tumors, grafted primary tumors, and graftedvations suggested the possibility that metastases in MTB/TAN
tumor metastases
animals might also remain dependent on Neu for growth.
Primary tumor MetastasisTo pursue this hypothesis, pulmonary metastases and pri-
Primary tumors grafts graftsmary tumors from chronically induced MTB/TAN mice were
Fully regressed 44/47 (94%) 8/14 (57%) 13/19 (68%)grafted onto the flanks of syngeneic hosts maintained on doxy-
Partially regressed, 2/47 (4%) 5/14 (36% 5/19 (26%)cycline. Following the outgrowth of these grafts, doxycycline
resumed growthwas withdrawn from graft recipients. 68% (13/19) of tumor grafts
Partially regressed, 1/47 (2%) 1/14 (7%) 1/19 (5%)from pulmonary metastases and a similar fraction (57%; 8/14)
no regrowthof grafts from primary mammary tumors regressed to a nonpal-
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oped the characteristic respiratory phenotype associated with increasingly aggressive properties, such as loss of hormone
dependence, resistance to chemotherapeutic agents, and thepulmonary metastases. These images confirmed the presence
of widespread pulmonary nodules (Figure 5A, middle column). ability to invade tissues and metastasize. This process of tumor
progression is ultimately responsible for cancer mortality. WhileAs before, withdrawal of doxycycline from these animals re-
sulted in the regression of primary mammary tumors as well as the reversibility of several oncogene-induced primary tumors
has been demonstrated using conditional transgenic mousethe resolution of their respiratory phenotype. Reimaging these
animals by MRI 30 days later revealed that nodules were no models, the impact of tumor progression on oncogene revers-
ibility has not been addressed in any system to date.longer detectable in the lungs (Figure 5A, right column). More-
over, histological analysis of the lungs from these animals con- We have developed a novel inducible transgenic mouse
model for HER2/Neu-overexpressing breast cancers that dis-firmed the absence of neoplastic disease (Figure 5B).
In aggregate, the high rate of metastasis in tumor-bearing plays many features of human tumor progression, including
invasion, metastasis, and recurrence. Given the highly aggres-MTB/TAN animals displaying a respiratory phenotype, the re-
producible resolution of this phenotype in animals taken off sive nature of both human and murine breast cancers overex-
pressing HER2/Neu, we considered the possibility that Neu-doxycycline, the regression of grafted pulmonary metastases,
and the regression of pulmonary metastases in vivo all suggest induced mammary carcinomas would continue to grow despite
downregulation of the initiating oncogenic stimulus. In contrast,that the vast majority of cells within most, if not all, pulmonary
metastases arising from Neu-induced mammary tumors remain we found that essentially all primary tumors induced by Neu
regress to a clinically undetectable state following transgenedependent upon continued Neu expression for maintenance of
the transformed state. deinduction by doxycycline withdrawal. Thus, despite the multi-
ple genetic and epigenetic alterations that occur during Neu-
induced mammary tumorigenesis, the vast majority of cellsFully regressed tumors recur in MTB/TAN animals
in the absence of doxycycline within these tumors remain dependent upon Neu for mainte-
nance of the transformed state. Surprisingly, we have also foundThe complete regression of Neu-induced invasive mammary
adenocarcinomas and metastases that we observed in MTB/ that extensive lung metastases arising in tumor-bearing animals
also rapidly and fully regress following the abrogation of NeuTAN mice was unexpected, since clinical experience indicates
that human epithelial malignancies are rarely, if ever, cured by expression. However, despite the reversibility of Neu-induced
primary tumors and metastases, we find that most if not alltreatment with a single agent. Rather, we anticipated that at
least some cells in Neu-induced tumors would have acquired animals in which Neu-induced mammary carcinomas have re-
gressed to a clinically undetectable state still harbor residualthe ability to grow in a Neu-independent manner. This fact
prompted us to examine MTB/TAN mice bearing fully regressed neoplastic disease long after the clinical disappearance of their
tumors. Moreover, these residual cells ultimately give rise totumors for evidence of tumor recurrence. Eleven MTB/TAN mice
in which doxycycline withdrawal had led to the complete regres- recurrent tumors that grow in a Neu-independent manner,
strongly suggesting that subpopulations of neoplastic mam-sion of all tumors were maintained off doxycycline and moni-
tored for tumor recurrences. A total of 8 tumors recurred in 7 mary epithelial cells are able to escape their requirement for
Neu to reestablish a malignant phenotype. These findings con-animals after an average of 153  93 days (range 27–300 days)
off doxycycline (Figure 6A). That these tumors represent recur- tradict the assertion that all oncogene-initiated events are re-
versible.rences of Neu-initiated tumors rather than the de novo formation
of tumors in the absence of doxycycline is strongly suggested The dependence of tumors on a single oncogene has pre-
viously been demonstrated in conditional transgenic mouseby our repeated observation that uninduced MTB/TAN animals
do not develop tumors, even over periods exceeding 18 months models for H-ras-induced melanomas, K-ras-induced adeno-
carcinomas of the lung, BCR-ABL-induced leukemias, and Myc-(n  13). Northern analysis failed to detect NeuNT transgene
expression in any of these recurrent tumors, indicating that induced leukemias, lymphomas, and islet cell tumors (Chin et
al., 1999; Felsher and Bishop, 1999; Huettner et al., 2000; Fishertumor recurrences are not merely a consequence of transgene
activation in the absence of doxycycline (Figure 6B). Similarly, et al., 2001; Pelengaris et al., 2002). This has led to the frequent
assumption that tumors induced by other oncogenes in otherNorthern analysis as well as anti-ErbB2 immunohistochemistry
failed to detect upregulation of endogenous ErbB2 in recurrent tissues will similarly remain dependent upon the initiating onco-
gene for maintenance of the transformed state. However, cur-tumors (data not shown).
Together, these findings strongly suggest that a subset of rent evidence challenges this view and suggests instead that
dependence upon an initiating oncogenic event is not a mono-cells within Neu-initiated tumors progress to a state that is
lithic property of tumors. For example, in marked contrast toindependent of Neu overexpression for survival and growth.
the near total reversibility of MYC-induced neoplasia reportedMore importantly, our observations demonstrate that despite
in the hematopoietic compartment and in pancreatic  cells,the near universal regression of Neu-initiated primary mammary
we have previously observed that the majority of tumors inducedtumors to a nonpalpable state, the majority of fully regressed
by MYC in the mammary gland do not remain dependent upontumor-bearing animals in this system harbor residual neoplastic
MYC for maintenance of the transformed state (D’Cruz et al.,disease for periods of up to a year following the clinical disap-
2001). In turn, the tendency of MYC to induce mammary tumorspearance of their tumors.
that are MYC-independent contrasts sharply with our current
findings regarding the near universal dependence of Neu-Discussion
induced mammary tumors on Neu. These observations empha-
size the importance of investigating the reversibility of differentThe evolution of human cancers is characterized by the progres-
sive selection and outgrowth of mutant clones that possess oncogenes and different tumor types individually. Given that
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Figure 5. MRI and histological analysis of the reversibility of NeuNT-induced pulmonary metastases in situ
A: Magnetic resonance images of lungs from an uninduced MTB/TAN animal (Uninduced, left column of panels), an MTB/TAN tumor-bearing animal on
doxycycline with the characteristic respiratory phenotype associated with pulmonary metastases (Induced, middle column of panels), and the same
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occurs. Consequently, since the vast majority of human cancers
are epithelial, investigating the phenomenon of oncogene-revers-
ibility in epithelial cell types in which oncogenes relevant to the
corresponding human cancers have been activated has obvious
clinical importance.
The potential impact of tumor progression on the reversibility
of oncogene-initiated events is an important issue that has criti-
cal clinical implications. In this regard, the dramatic regression
of invasive primary tumors that we observed following transgene
deinduction raised the question of whether distant metastases
would remain similarly dependent upon an initiating genetic
lesion for maintenance and growth. To be sure, the observation
that primary tumors are reversible does not imply that metasta-
ses arising from these tumors will also be reversible. Indeed, it
might reasonably be predicted that the same adaptations that
confer the aggressive growth properties required for Neu-
induced mammary tumor cells to metastasize might also facili-
tate Neu-independent tumor growth and maintenance. If so,
one would predict that metastatic lesions arising from Neu-
induced tumors would be more resistant to the effects of down-
regulating Neu expression than cells from the primary mammary
tumors. In contrast to this expectation, we have demonstrated
that extensive lung metastases arising in animals bearing Neu-
induced mammary tumors rapidly and fully regress following
the abrogation of Neu expression. Our results demonstrate that
despite the acquisition of mutations that render tumor cells able
to invade the vasculature, disseminate, survive, and establish
growth at distant sites, the vast majority of tumor cells within
even the most advanced stages of malignancy remain depen-
dent upon a single genetic mutation for growth and maintenanceFigure 6. MTB/TAN mice harboring fully regressed tumors develop Neu-inde-
of the transformed phenotype. Thus, in contrast to the generalpendent tumor recurrences
presumption that the same genetic events that contribute toA: Representative graphs of MTB/TAN tumors displaying growth on doxycy-
cline, full regression following doxycycline withdrawal, and recurrence in tumor progression also render metastatic lesions less respon-
the absence of doxycycline. sive to phamacologic intervention, our findings indicate that
B: Northern analysis of total RNA from primary and recurrent tumors har-
advanced tumor stage per se does not render malignant cellsvested from MTB/TAN animals. Primary tumor samples were obtained by
independent of Neu signaling for their maintenance.biopsy of tumors in animals maintained on doxycycline. Recurrent tumors
arose following doxycycline withdrawal and full regression of the primary Recent findings from a number of inducible transgenic
tumor to a nonpalpable size. The blot was probed with a DNA fragment mouse models of cancer have been interpreted to suggest the
specific for Neu. 28S rRNA is shown as a loading control. possibility that many oncogene-initiated events may be revers-
ible and that human tumors may be similarly reversible with
targeted therapy. Indeed, our finding that reversing a single
oncogenic mutation results in the complete regression of bothwe have analyzed both Neu and c-MYC-initiated mammary tu-
primary tumors and metastatic disease is consistent with thismorigenesis in the same tissue compartment, in an identical
notion. However, since metastatic epithelial cancers are typi-genetic background, and using the same MMTV-rtTA transacti-
cally incurable, even with the use of combinatorial therapies,vator line, our findings imply that the likelihood of developing
the complete reversibility of oncogene-initiated events is clearlya transgene-independent tumor is an intrinsic property of the
inconsistent with clinical experience. In fact, we find that despiteinitiating oncogenic event. That is, different oncogenic pathways
the near universal regression of Neu-initiated primary mammaryare likely to have different probabilities of being rendered dis-
tumors to a nonpalpable state, the majority of mice bearingpensable for tumor maintenance and growth, and the propensity
fully regressed mammary tumors harbor residual foci of viableof cancers to become oncogene-independent is therefore al-
neoplastic cells even after periods of up to a year following themost certainly a function both of the oncogene that is activated
and of the cellular compartment in which oncogene activation clinical disappearance of their tumors. Moreover, these foci of
animal as that imaged in the middle column 30 days after withdrawal of doxycycline (Deinduced, right column of panels). Each column of panels represents
three coronal sections, progressing anterior to posterior, taken at equivalent levels from each animal. Focal areas of metastasis are indicated by arrows.
A primary tumor is denoted by an asterisk.
B: H&E-stained lung sections from an uninduced MTB/TAN animal (Uninduced), an MTB/TAN animal sacrificed while on doxycycline that harbored grossly
visible pulmonary metastases (Induced), and the Deinduced MTB/TAN animal imaged in A from which doxycycline had been withdrawn (Deinduced).
Magnification 50 (upper row) and 200 (lower row).
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Luciferase assaysresidual disease ultimately lead to the emergence of recurrent
Snap-frozen mammary gland tissue was analyzed using the Luciferase Assaytumors that grow in a Neu-independent manner. Whether or
System (Promega) per manufacturer’s instructions. Tissue was dounced innot these tumors have escaped their dependence on Neu by
100 l 1 Reporter Lysis Buffer and lysates were centrifuged at 4C for 1activating downstream components of the Neu pathway re-
min at 14,000 rpm. 20 l of lysate was injected with Luciferase Assaymains to be investigated. In either case, however, our observa-
Substrate and activity was read in a Monolight 2010 luminometer. Luciferase
tion that residual Neu-induced tumor cells typically progress to activity levels were normalized to total protein levels as determined by Lowry
a Neu-independent state mirrors the propensity of human tumor Protein Assay (BioRad).
cells to progress to more advanced stages of malignancy and
demonstrates that all oncogene-initiated events are not revers- Whole mounts and histology
ible. These findings contrast with the apparent lack of progres- Number 3 or 4 mammary glands were mounted on glass slides, fixed over-
sion to oncogene-independent states in several other condi- night in 4% paraformaldehyde, and transferred to 70% ethanol. For whole
mounts, glands were rinsed in water for 5 min and stained in a filteredtional transgenic models for cancer.
solution of 0.2% carmine (Sigma) and 0.5% aluminum potassium sulfate forRecently, Jain et al. demonstrated that even brief inactiva-
1–3 days. Glands were then dehydrated sequentially through 70%, 90%,tion of MYC in osteogenic sarcoma cells results in the sustained
and 100% ethanol for 15 min each, then defatted and stored in methylregression of these tumors and, furthermore, that MYC trans-
salicylate. For histological analysis, fixed glands were blocked in paraffin,gene deinduction protects these mesenchymal cells from sub-
sectioned, and stained with hematoxylin and eosin.sequent MYC-induced tumorigenesis (Jain et al., 2002). In con-
trast to this observation, we find that even prolonged inactivation
Immunohistochemistry
of Neu fails to yield sustained regression of Neu-induced mam- For BrdU analysis, animals were injected with 0.05 mg BrdU per gram body
mary tumors, as these tumors instead commonly recur in a Neu- weight two hours prior to sacrifice. The number four mammary gland was
independent manner. As such, the phenomenon described by harvested and fixed overnight in 4% paraformaldehyde, transferred to 70%
Jain et al. for MYC in transplanted osteogenic sarcoma cells ETOH, and embedded in paraffin. 5 m sections on ProbeOn Plus (Fisher)
does not appear to apply to Neu in intact mammary adenocarci- slides were dewaxed in xylene, then sequentially rehydrated in 100%, 95%,
nomas. Given the important biological role for Neu/HER2 in and 70% ETOH, followed by phosphate buffered saline (PBS). Sections were
pretreated in 2N HCl for 20 min at RT, washed in 0.1 M Borate buffer (pHhuman breast cancers, and the availability and increasing use
8.5)  2, and rinsed in PBS. BrdU immunohistochemistry was performedof an anti-HER2 therapy in the clinic, our observations suggest
using the Vectastain Elite ABC Kit (Vector Laboratories), rat anti-BrdU IgGthat attempts to extrapolate the findings of Jain et al. to human
(Vector), and a secondary biotinylated rabbit anti-rat IgG antibody accordingepithelial malignancies should be made cautiously.
to manufacturer’s instructions. Sections were counterstained for 10 min inFinally, the importance of developing chemotherapeutic
0.5% (w/v) methyl green in 1.0 M NaOAc (pH 4.0).strategies that target multiple pathways in epithelial cancers is
TUNEL analysis was performed using the Apoptag Peroxidase Kit (In-
highlighted by clinical experience as well as by our observation
tergen) according to manufacturer’s instructions. Sections were pretreated
that Neu-induced mammary tumors typically progress to a Neu- in Proteinase K (20 g/ml) for 15 min at RT, washed in deionized water twice
independent state. Since an increasing number of therapies for 2 min each, incubated in equilibration buffer, then incubated at 37C for
targeting molecular pathways known to play a role in cancer 1 hr with a 1:10 Dilution of TdT Enzyme in 1 reaction buffer. Reactions
are either in clinical use or are under development, elucidation were terminated, developed using anti-digoxigenin-Alkaline Phosphatase
of the mechanisms by which tumor cells escape their depen- Fab fragments (BMB) and nitroblue tetrazolium chloride per manufacturer’s
dence on these targeted pathways represents a critical next instructions, and counterstained in methyl green.
For Neu/ErbB2 IHC, paraffin-embedded tumors were sectioned at 5 mstep in cancer research. Such knowledge will facilitate the devel-
and antigen retrieval was accomplished by microwaving in citrate buffer.opment of more effective therapeutic approaches that achieve
Anti-ErbB2 antibody PH511.xs (Binding Site) was detected using the Vectortumor cell eradication by targeting both primary oncogenic path-
ABC kit. Images were captured using a Kontronic camera model 8102 onways as well as secondary pathways of tumor escape. By per-
an Olympus BH2 microscope, digitized using Photoshop 6.0 with the Kontronmitting the temporal dissection of tumor initiation, establish-
ProgRes plugin module, color enhanced, and balanced for contrast.ment, progression, metastasis, and recurrence, we believe that
this model system provides a valuable opportunity for examining
Northern analysisthe molecular events that contribute to the progression of Neu-
Snap-frozen tissue was homogenized in guanidine thiocyanate supple-
induced mammary carcinomas as well as for analyzing the na-
mented with 7 l/ml 2-mercaptoethanol, and RNA isolated by centrifugation
ture of residual neoplastic disease. through cesium chloride as previously described (Rajan et al., 1996). Total
RNA (3 g per blot) was separated on a 1% LE agarose gel, and passivelyExperimental procedures
transferred to Gene Screen (NEN). Northern hybridization was performed
per manufacturer’s instructions using PerfectHyb Plus Hybridization BufferAnimals and tissues
(Sigma) and a 32P-labeled cDNA probe spanning the 3 end of the Neu codingTetO-NeuNT mice were engineered by cloning the coding sequence of acti-
sequence and the 5 end of the IRES.vated Neu (a gift of William Muller) downstream of the tet operator in pTet-
Splice (Gibco-BRL). An IRES-Firefly Luciferase sequence was cloned down-
stream of NeuNT using the IRES from MIGR1 (a gift of Warren Pear) and Tumor grafting
Luciferase from pGL3-Basic (Promega). Founder lines were generated by Chronically induced tumor-bearing MTB/TAN animals that had developed a
injecting the linearized contruct into fertilized oocytes harvested from super- characteristic phenotype of ruffled fur and labored breathing were sacrificed.
ovulated FVB mice. Primary tumors and grossly visible pulmonary metastases were harvested
Transgenic mice were housed under barrier conditions with a 12 hr and chilled on ice in DMEM (Cellgro) prior to being grafted subcutaneously
light/dark cycle and access to food and water ad libitum. Induced animals
onto the flanks of anesthetized recipient animals. Recipient animals werewere administered doxycycline (0.1–2 mg/ml) (Sigma) in their drinking water,
then placed on doxycycline treatment, and graft outgrowths were biopsiedwhich was replaced weekly. Animals were inspected for tumors, and existing
when they reached a size of approximately 15  15 mm2 . Grafted animalstumors were measured weekly. At the indicated times of sacrifice, animals
were maintained on doxycycline after biopsy to document continued graftwere killed by CO2 asphyxiation and tissues were either snap-frozen on
growth, at which time doxycycline was withdrawn and the regression behav-dry ice for protein or RNA analysis, or fixed in 4% paraformaldehyde for
morphological and immunohistochemical analysis. ior of the grafts was monitored.
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bacher, L., Wolter, J.M., Paton, V., Shak, S., Lieberman, G., and Slamon,Magnetic resonance imaging
D.J. (1999). Multinational study of the efficacy and safety of humanizedAnimals were lightly anesthetized using a 1% isoflurane air mixture. Subder-
anti-HER2 monoclonal antibody in women who have HER2-overexpressingmal needle electrodes were placed in the two forelegs, a thermistor was
metastatic breast cancer that has progressed after chemotherapy for meta-placed rectally, and animals were mounted in a home-built 5  9 cm linearly
static disease. J. Clin. Oncol. 17, 2639–2648.polarized birdcage coil. All MR imaging was performed on a 4.7T horizontal
bore INOVA spectrometer (Varian, Palo Alto, CA) equipped with 12 cm 25 D’Cruz, C.M., Gunther, E.J., Boxer, R.B., Hartman, J.L., Sintasath, L., Moody,
g/cm gradients. ECG, respiration, and core body temperature were moni- S.E., Cox, J.D., Ha, S.I., Belka, G.K., Golant, A., et al. (2001). c-MYC induces
tored using a prototype MR compatible small animal monitoring device (SA mammary tumorigenesis by means of a preferred pathway involving sponta-
Instruments, Bayshore, NY). This device also generated the signals for gating neous Kras2 mutations. Nat. Med. 7, 235–239.
the spectrometer and regulating a warm air source used to maintain body
Felsher, D.W., and Bishop, J.M. (1999). Reversible tumorigenesis by MYC
temperature. Combined respiratory and cardiac gating was used in all studies
in hematopoietic lineages. Mol. Cell 4, 199–207.
in order to minimize motion artifacts. Images were generated using the
Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W.,standard spin echo sequence with TE/TR  15/250 msec, a slice thickness
Lizak, M.J., Whitsett, J.A., Koretsky, A., and Varmus, H.E. (2001). Inductionof 1 mm, a field of view of 6  3 cm, and a matrix of 256  128.
and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras
transgene in the presence and absence of tumor suppressor genes. GenesAcknowledgments
Dev. 15, 3249–3262.
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